Key result
Weekly recombinant soluble thrombomodulin maintains chronic DIC resolution in dissecting aortic aneurysm.
Why the study?
The optimal frequency of recombinant human soluble thrombomodulin administration after resolution of chronic DIC in patients with dissecting aortic aneurysm was unclear.
Does intermittent administration of recombinant human soluble thrombomodulin control chronic DIC in a patient with dissecting aortic aneurysm?
Case Report (n=1)
Does intermittent administration of recombinant human soluble thrombomodulin control chronic DIC in a patient with dissecting aortic aneurysm?
Once-weekly outpatient administration of recombinant human soluble thrombomodulin successfully maintained control of chronic DIC in a patient with a dissecting aortic aneurysm.
Subcutaneous heparin calcium may enable outpatient management of chronic DIC in aortic aneurysm; leaves open need for controlled trials to confirm safety and efficacy.
Chronic disseminated intravascular coagulation (DIC) is a rare but life-threatening complication of dissecting aortic aneurysm. Although anticoagulant therapy may often proves effective for controlling DIC itself, patients would have to be hospitalized for a long period due to continuous infusion therapy. Subcutaneous injection of a highly concentrated preparation of heparin calcium may offer one alternative treatment for DIC; however, daily subcutaneous use of heparin for the treatment of DIC has impaired quality of life (QOL). The other alternative therapy is intravenous administration of recombinant human soluble thrombomodulin (rTM), which includes the active extracellular domain of thrombomodulin. Reportedly, rTM effectively resolves DIC by only 6 consecutive days of administration; however, how frequently rTM should be administered after the resolution of chronic DIC to have good control of it has been unclear. We report herein a case of chronic DIC complicated with dissecting aortic aneurysm, whose resolution of chronic DIC achieved by 6 consecutive days of rTM has been maintained by once a week administration of rTM on an outpatient basis.
No takes yet. Share an insight, caveat, or question.
Iyama et al. (2012) conducted a case report in Chronic disseminated intravascular coagulation (DIC) complicated with dissecting aortic aneurysm (n=1). Recombinant human soluble thrombomodulin (rTM) was evaluated on Resolution and control of chronic DIC. Once-weekly administration of recombinant human soluble thrombomodulin successfully maintained the resolution of chronic DIC in a patient with a dissecting aortic aneurysm on an outpatient basis.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: